Literature DB >> 32040239

Xenogeneic transplantation of human WJ-MSCs rescues mice from acute radiation syndrome via Nrf-2-dependent regeneration of damaged tissues.

Mayuri Bandekar1,2, Dharmendra K Maurya1,3, Deepak Sharma1,3, Rahul Checker1,3, Vikram Gota4, Nigamananda Mishra5, Santosh K Sandur1,3.   

Abstract

There is an unmet medical need for radiation countermeasures that can be deployed for treatment of exposed individuals during ionizing radiation (IR) accidents or terrorism. Wharton's jelly mesenchymal stem cells (WJ-MSCs) from human umbilical cord have been shown to avoid allorecognition and induce a tissue-regenerating microenvironment, which makes them an attractive candidate for mitigating IR injury. We found that WJ-MSCs protected mice from a lethal dose of IR even when transplanted up to 24 hours after irradiation, and a combination of WJ-MSCs and antibiotic (tetracycline) could further expand the window of protection offered by WJ-MSCs. This combinatorial approach mitigated IR-induced damage to the hematopoietic and gastrointestinal system. WJ-MSCs increased the serum concentration of the cytoprotective cytokines granulocyte colony-stimulating factor (G-CSF) and IL-6 in mice. Knockdown of G-CSF and IL-6 in WJ-MSCs before injection to lethally irradiated mice or transplantation of WJ-MSCs to lethally irradiated Nrf-2 knockout mice significantly nullified the therapeutic protective efficacy. Hence, WJ-MSCs could be a potential cell-based therapy for individuals accidentally exposed to radiation.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  animal models: murine; basic (laboratory) research; cell death: apoptosis; cytokine receptors; cytokines; immune modulation; immunosuppression; regenerative medicine; science; stem cells; tissue injury and repair; translational research; xenotransplantation

Mesh:

Year:  2020        PMID: 32040239     DOI: 10.1111/ajt.15819

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

1.  Soluble factors secreted by human Wharton's jelly mesenchymal stromal/stem cells exhibit therapeutic radioprotection: A mechanistic study with integrating network biology.

Authors:  Dharmendra Kumar Maurya; Mayuri Bandekar; Santosh Kumar Sandur
Journal:  World J Stem Cells       Date:  2022-05-26       Impact factor: 5.247

2.  Use of MSCs and MSC-educated macrophages to mitigate hematopoietic acute radiation syndrome.

Authors:  Raghavan Chinnadurai; Matthew H Forsberg; John A Kink; Peiman Hematti; Christian M Capitini
Journal:  Curr Stem Cell Rep       Date:  2020-08-08

Review 3.  Preclinical Studies and Clinical Prospects of Wharton's Jelly-Derived MSC for Treatment of Acute Radiation Syndrome.

Authors:  Mayuri Bandekar; Dharmendra K Maurya; Deepak Sharma; Santosh K Sandur
Journal:  Curr Stem Cell Rep       Date:  2021-04-28

Review 4.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 5.  Hematopoietic Stem Cells and Mesenchymal Stromal Cells in Acute Radiation Syndrome.

Authors:  Liren Qian; Jian Cen
Journal:  Oxid Med Cell Longev       Date:  2020-08-08       Impact factor: 6.543

6.  Dichotomic Potency of IFNγ Licensed Allogeneic Mesenchymal Stromal Cells in Animal Models of Acute Radiation Syndrome and Graft Versus Host Disease.

Authors:  Raghavan Chinnadurai; Paul D Bates; Keith A Kunugi; Kwangok P Nickel; Larry A DeWerd; Christian M Capitini; Jacques Galipeau; Randall J Kimple
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

7.  Allogeneic adipose-derived stem cells mitigate acute radiation syndrome by the rescue of damaged bone marrow cells from apoptosis.

Authors:  Somaiah Chinnapaka; Katherine S Yang; Yasamin Samadi; Michael W Epperly; Wen Hou; Joel S Greenberger; Asim Ejaz; J Peter Rubin
Journal:  Stem Cells Transl Med       Date:  2021-03-16       Impact factor: 6.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.